EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+7.83%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.92B
AUM Growth
-$347M
Cap. Flow
-$416M
Cap. Flow %
-14.23%
Top 10 Hldgs %
63.83%
Holding
68
New
13
Increased
7
Reduced
7
Closed
4
Avg Time Held Equity + Options
1.6 years
Top 10 Avg Time Held Equity + Options
1.5 years
Top 20 Avg Time Held Equity + Options
1.9 years
Avg Time Held Equity only
1.6 years
Top 10 Avg Time Held Equity only
1.5 years
Top 20 Avg Time Held Equity only
1.9 years

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$75.9M
2
VRDN icon
Viridian Therapeutics
VRDN
+$32M
3
MBX icon
MBX Biosciences
MBX
+$26.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$23.3M
5
RLAY icon
Relay Therapeutics
RLAY
+$18.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$222M
2
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$170M
3
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$153M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$30.5M
5
ITOS icon
iTeos Therapeutics
ITOS
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Miscellaneous 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APLS icon
1
DELISTED
Apellis Pharmaceuticals
APLS
$343M 11.74%
11,890,843
+283,418
+2% +$10.5M
2021 Q4
11 quarters
ANAB icon
2
AnaptysBio
ANAB
$1.4B
$261M 8.94%
7,794,996
+273,972
+4% +$9.36M
2019 Q4
19 quarters
CRNX icon
3
DELISTED
Crinetics Pharmaceuticals
CRNX
$219M 7.5%
4,288,120
+132,745
+3% +$6.85M
2021 Q4
11 quarters
PRTA icon
4
Prothena Corp
PRTA
$430M
$194M 6.63%
11,584,280
– –
2018 Q4
23 quarters
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$13.6B
$190M 6.51%
1,706,469
+692,517
+68% +$75.9M
2023 Q2
5 quarters
ZYME icon
6
Zymeworks
ZYME
$1.78B
$169M 5.77%
13,437,473
– –
2022 Q4
7 quarters
ARVN icon
7
Arvinas
ARVN
$446M
$166M 5.67%
6,726,491
– –
2021 Q4
11 quarters
KURA icon
8
Kura Oncology
KURA
$855M
$113M 3.88%
5,806,871
– –
2015 Q4
35 quarters
XNCR icon
9
Xencor
XNCR
$1.74B
$107M 3.67%
5,330,416
– –
2018 Q4
23 quarters
TNGX icon
10
Tango Therapeutics
TNGX
$3.74B
$103M 3.51%
13,330,736
– –
2020 Q3
16 quarters
JANX icon
11
Janux Therapeutics
JANX
$1.05B
$66.8M 2.29%
1,469,818
– –
2024 Q2
1 quarter
CRSP icon
12
CRISPR Therapeutics
CRSP
$4.86B
$65.3M 2.23%
1,389,276
– –
2024 Q1
2 quarters
IMNM icon
13
Immunome
IMNM
$2.03B
$56.7M 1.94%
3,879,415
– –
2023 Q4
3 quarters
NGNE icon
14
Neurogene
NGNE
$444M
$53.3M 1.83%
1,271,342
– –
2023 Q4
3 quarters
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$51.5M 1.76%
3,223,851
-2,490,553
-44% -$30.5M
2021 Q2
13 quarters
VRDN icon
16
Viridian Therapeutics
VRDN
$2.08B
$44.6M 1.53%
+1,958,847
New +$32M
2024 Q3
0 quarters
NUVB icon
17
Nuvation Bio
NUVB
$1.64B
$44M 1.51%
19,209,643
– –
2021 Q1
14 quarters
THRD icon
18
DELISTED
Third Harmonic Bio
THRD
$43.1M 1.48%
3,182,444
– –
2023 Q1
6 quarters
PCVX icon
19
Vaxcyte
PCVX
$10.6B
$40.3M 1.38%
352,464
+52,464
+17% +$4.73M
2024 Q1
2 quarters
MRSN icon
20
DELISTED
Mersana Therapeutics
MRSN
$36.6M 1.25%
774,588
– –
2023 Q3
4 quarters
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.2B
$35M 1.2%
3,418,068
– –
2020 Q2
17 quarters
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$34.8M 1.19%
757,576
– –
2024 Q1
2 quarters
EWTX icon
23
Edgewise Therapeutics
EWTX
$4.02B
$33.4M 1.14%
1,250,385
– –
2021 Q1
14 quarters
MBX icon
24
MBX Biosciences
MBX
$2.35B
$30.5M 1.05%
+1,175,809
New +$26.9M
2024 Q3
0 quarters
NMRA icon
25
Neumora Therapeutics
NMRA
$66.6M
$27.4M 0.94%
2,071,450
– –
2023 Q3
4 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2024 Portfolio in Review

As of Q3 2024, EcoR1 Capital held 68 positions worth $2.92B, down 11% from $3.27B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

EcoR1 Capital withdrew a net $416M in Q3 2024, closing 4 positions and reducing 7 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $222M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Viridian Therapeutics worth $44.6M.

  • EcoR1 Capital's largest Q3 2024 buy was Viridian Therapeutics: 1,958,847 shares worth $44.6M.
  • EcoR1 Capital added most to Jazz Pharmaceuticals in Q3 2024, an estimated $75.9M increase.
  • EcoR1 Capital's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $153M.
  • EcoR1 Capital fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $222M.
  • EcoR1 Capital's ten largest holdings make up 64% of its $2.92B portfolio in Q3 2024.
  • EcoR1 Capital opened 13 new positions and closed 4 in Q3 2024.
  • EcoR1 Capital's portfolio value fell 11% quarter-over-quarter to $2.92B.

Based on EcoR1 Capital's 13F filing for Q3 2024, filed 14 Nov 2024.